Testosterone Replacement in Postmenopausal Women With Stress Urinary Incontinence
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03116087 |
Recruitment Status :
Completed
First Posted : April 14, 2017
Last Update Posted : August 9, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The overall objective of this study is to establish if testosterone replacement in post-menopausal women with low testosterone levels and stress urinary incontinence (SUI) will lead to improvement in symptoms of SUI.
This study is a prospective, randomized, double-blind, placebo-controlled, parallel-group, clinical trial and will involve sixty (60) post-menopausal women with clinically diagnosed stress urinary incontinence and low testosterone concentrations. These subjects will enter the control period, which involves the baseline measurements of pelvic floor muscle volume and strength, amounts of urine leakage in 24-hour period, urodynamic parameters, and quality of life using Incontinence Impact Questionnaire and Urogenital Distress Inventory. Subjects are then randomly assigned to either placebo (30 subjects) or 300 mcg/twice-weekly testosterone patch (30 subjects) group. Both the subjects and investigators will be blinded. The duration of the testosterone/control study will be 36 weeks, with weeks 1-3 screening/control period, 4-28 application of placebo or testosterone patches and 29-36 recovery time/assessment of effects.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Stress Urinary Incontinence | Drug: Testosterone patch Drug: Placebo | Not Applicable |
Primary Outcome Measure:
Our primary outcome measure is the change in levator ani muscle volume with correlation in improvement in stress incontinence. These will be assessed by MRI, urodynamic studies and pad tests. [Time Frame: 36 weeks]
Secondary Outcome Measures:
Our secondary outcome measures are: [Time Frame: 36 weeks]
- Change in urodynamic measurements including urethral pressure profile, cough stress profile, maximum urethral closure pressure, Valsalva leak point pressure, and pressure transmission ratios.
- Change in pelvic floor muscle strength as measured with a perineometer.
- Change in amounts of urinary leakage (in a 24 hour period) using the Pad Test.
- Change in subjective quality of life as it relates to incontinence using the Incontinence Impact Questionnaire, Urogenital Distress Inventory and Incontinence Diary.
- Change in hormone levels including total and free testosterone, dihydrotestosterone (DHT), estradiol 17 B, and sex hormone binding globulin (SHBG).
- Change in complete blood count, chem 20, lipid profile (total cholesterol, triglyceride, HDL, LDL) and physical examination as compared to the baseline before treatment.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Testosterone Replacement in Postmenopausal Women With Stress Urinary Incontinence |
Actual Study Start Date : | March 1, 2007 |
Actual Primary Completion Date : | May 31, 2018 |
Actual Study Completion Date : | May 31, 2018 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Testosterone patch
Testosterone patches
|
Drug: Testosterone patch
300 mcg testosterone patches or placebo applied twice weekly
Other Name: Testosterone patches |
Placebo Comparator: Placebo
Placebo patches
|
Drug: Placebo
Placebo patch
Other Name: Placebo patch |
- Our primary outcome measure is the change in levator ani muscle volume with correlation in improvement in stress incontinence. [ Time Frame: 36 weeks ]This outcome will be assessed by MRI, urodynamic studies and pad tests.
- Change in urethral pressure profile. [ Time Frame: 36 weeks ]This outcome will be evaluated with urodynamic measurement of urethral pressure (in cm H2O) along the urethra.
- Change in pelvic floor muscle strength. [ Time Frame: 36 weeks ]This outcome will be measured with a perineometer.
- Change in amounts of urinary leakage. [ Time Frame: 36 weeks ]This will be measured with the Pad Test ( in a 24 hour period).
- Change in subjective quality of life as it relates to incontinence. [ Time Frame: 36 weeks ]This outcome will be measured with a validated questionnaire and compared with the baseline before treatment.
- Change in hormone levels including total and free testosterone, dihydrotestosterone (DHT), estradiol 17 B, sex hormone binding globulin (SHBG). [ Time Frame: 36 weeks ]These will be measured at the baseline (before treatment) and then every four weeks during the treatment and recovery periods and compared with the baseline.
- Change in laboratory values. [ Time Frame: 36 weeks ]The blood sample will be collected for laboratory measurement (CBC, chem 20, lipid profile) at the baseline (before treatment) and then every four weeks during the treatment and recovery periods and compared with the baseline.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 45 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Inclusion Criteria:
- Ambulatory, postmenopausal women
- The presence of stress urinary incontinence, defined as involuntary urine loss during physical activity, cough, or sneeze.
- Able to understand and give informed consent.
- Those on estrogen replacement therapy prior to the study should have been on a stable regimen for at least three months. For those who are not on estrogen replacement therapy prior to the study, will not be started on estrogen for the duration of the study.
- Normal Pap smear and mammogram in the preceding 12 months by history and chart review.
Exclusion Criteria:
- Uncontrolled depression as assessed by history and physical exam.
- Those with any acute or chronic illness, malignant disease, fever of known or unknown origin, diabetes mellitus (fasting blood glucose > 126 mg/dl), or uncontrolled hypertension (defined as blood pressure greater than 160/100).
- Current urinary tract infection (UTI). For those with acute UTI, treatment will be given and repeat culture should be negative before enrollment.
- Severe obesity defined as body mass index of greater than 40 kg/m2.
- Current or recent (last 6 months) use of illicit drugs (which may affect appetite, food intake, metabolism, and/or compliance with the protocol).
- Current or recent (last 6 months) alcohol or drug dependence.
- Significant liver function abnormalities defined as AST, ALT, or alkaline phosphatase value of greater than three times the upper limit of normal in our Clinical Pathology Laboratory, or serum bilirubin levels of greater than 2 mg/dl.
- History of breast or endometrial cancer.
- History of hyperandrogenic disorders such as hirsutism and polycystic ovary disease.
- Previous intolerance to testosterone.
- Women with abnormal PAP smears or mammograms will be included only after they have been evaluated by their gynecologists and breast and uterine/cervical cancers have been excluded by appropriate diagnostic tests.
- Women with significant dementia as assessed by history and physical exam.
- Those with disabilities that would prevent them from participating in the outcome testing, including tests of pelvic floor strength (e.g. severe arthritis, Parkinson's disease, stroke, or myopathy).
- Those who have received in the preceding three months drugs known to affect testosterone production or metabolism such as Ketoconazole, Megace, and or anabolic/androgenic steroids.
- Because of their age and post-menopausal status, spontaneous pregnancy is unlikely. Regardless, women who are pregnant, seeking to become pregnant in the next six months, or breastfeeding will not be included.
- Subjects who cannot have an MRI due to metal implants or pacemaker.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03116087
United States, California | |
Charles R. Drew University of Medicine and Science | |
Los Angeles, California, United States, 90059 |
Principal Investigator: | Matthew H Ho, MD | Charles R. Drew University |
Responsible Party: | Matthew Ho, Associate Professor, Charles Drew University of Medicine and Science |
ClinicalTrials.gov Identifier: | NCT03116087 |
Other Study ID Numbers: |
5-U54-HD041748-03-D227F |
First Posted: | April 14, 2017 Key Record Dates |
Last Update Posted: | August 9, 2018 |
Last Verified: | August 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Plan to share IPD: Presentation (grand rounds, scientific meetings) and peer-reviewed publications. |
Postmenopausal women |
Urinary Incontinence Enuresis Urinary Incontinence, Stress Urination Disorders Urologic Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Male Urogenital Diseases Lower Urinary Tract Symptoms Urological Manifestations Behavioral Symptoms Elimination Disorders |
Mental Disorders Methyltestosterone Testosterone Testosterone undecanoate Testosterone enanthate Testosterone 17 beta-cypionate Androgens Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents, Hormonal Antineoplastic Agents Anabolic Agents |